Barclays’s Ovid Therapeutics OVID Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $0 | Sell |
71
-63,847
| -100% | – | ﹤0.01% | 4502 |
|
|
2025
Q1 | $19K | Sell |
63,918
-29,389
| -31% | -$8.74K | ﹤0.01% | 4068 |
|
|
2024
Q4 | $87K | Buy |
93,307
+9,132
| +11% | +$8.52K | ﹤0.01% | 3828 |
|
|
2024
Q3 | $98K | Buy |
84,175
+63,702
| +311% | +$74.2K | ﹤0.01% | 3755 |
|
|
2024
Q2 | $15K | Sell |
20,473
-21,663
| -51% | -$15.9K | ﹤0.01% | 3940 |
|
|
2024
Q1 | $128K | Sell |
42,136
-39,924
| -49% | -$121K | ﹤0.01% | 3552 |
|
|
2023
Q4 | $264K | Buy |
82,060
+71,280
| +661% | +$229K | ﹤0.01% | 3383 |
|
|
2023
Q3 | $41K | Sell |
10,780
-1,175
| -10% | -$4.47K | ﹤0.01% | 3677 |
|
|
2023
Q2 | $40K | Buy |
+11,955
| New | +$40K | ﹤0.01% | 3766 |
|
|
2021
Q4 | – | Sell |
-8,218
| Closed | -$28K | – | 3657 |
|
|
2021
Q3 | $28K | Sell |
8,218
-27,009
| -77% | -$92K | ﹤0.01% | 3537 |
|
|
2021
Q2 | $137K | Sell |
35,227
-4,850
| -12% | -$18.9K | ﹤0.01% | 3034 |
|
|
2021
Q1 | $161K | Buy |
40,077
+24,718
| +161% | +$99.3K | ﹤0.01% | 3211 |
|
|
2020
Q4 | $35K | Sell |
15,359
-10,276
| -40% | -$23.4K | ﹤0.01% | 3285 |
|
|
2020
Q3 | $147K | Buy |
25,635
+2,061
| +9% | +$11.8K | ﹤0.01% | 2880 |
|
|
2020
Q2 | $173K | Buy |
+23,574
| New | +$173K | ﹤0.01% | 2876 |
|
|
2019
Q3 | – | Sell |
-267
| Closed | – | – | 4331 |
|
|
2019
Q2 | $0 | Sell |
267
-3,456
| -93% | – | ﹤0.01% | 4351 |
|
|
2019
Q1 | $7K | Buy |
+3,723
| New | +$7K | ﹤0.01% | 4045 |
|
|
2018
Q4 | – | Sell |
-4,938
| Closed | -$28K | – | 4295 |
|
|
2018
Q3 | $28K | Buy |
4,938
+3,518
| +248% | +$19.9K | ﹤0.01% | 3872 |
|
|
2018
Q2 | $11K | Sell |
1,420
-1,118
| -44% | -$8.66K | ﹤0.01% | 3871 |
|
|
2018
Q1 | $18K | Buy |
2,538
+1,737
| +217% | +$12.3K | ﹤0.01% | 3862 |
|
|
2017
Q4 | $8K | Buy |
801
+683
| +579% | +$6.82K | ﹤0.01% | 3848 |
|
|
2017
Q3 | $1K | Buy |
118
+114
| +2,850% | +$966 | ﹤0.01% | 3941 |
|
|
2017
Q2 | $0 | Buy |
+4
| New | – | ﹤0.01% | 4016 |
|